These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31402867)

  • 1. Loxapine for Treatment of Patients With Refractory, Chemotherapy-Induced Neuropathic Pain: A Prematurely Terminated Pilot Study Showing Efficacy But Limited Tolerability.
    Schmiedl S; Peters D; Schmalz O; Mielke A; Rossmanith T; Diop S; Piefke M; Thürmann P; Schmidtko A
    Front Pharmacol; 2019; 10():838. PubMed ID: 31402867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slack channels expressed in sensory neurons control neuropathic pain in mice.
    Lu R; Bausch AE; Kallenborn-Gerhardt W; Stoetzer C; Debruin N; Ruth P; Geisslinger G; Leffler A; Lukowski R; Schmidtko A
    J Neurosci; 2015 Jan; 35(3):1125-35. PubMed ID: 25609627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a Small Molecule Activator of Slack (Kcnt1) Potassium Channels That Significantly Reduces Scratching in Mouse Models of Histamine-Independent and Chronic Itch.
    Balzulat A; Zhu WF; Flauaus C; Hernandez-Olmos V; Heering J; Sethumadhavan S; Dubiel M; Frank A; Menge A; Hebchen M; Metzner K; Lu R; Lukowski R; Ruth P; Knapp S; Müller S; Steinhilber D; Hänelt I; Stark H; Proschak E; Schmidtko A
    Adv Sci (Weinh); 2024 Apr; 11(15):e2307237. PubMed ID: 38350720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antipsychotic drug loxapine is an opener of the sodium-activated potassium channel slack (Slo2.2).
    Biton B; Sethuramanujam S; Picchione KE; Bhattacharjee A; Khessibi N; Chesney F; Lanneau C; Curet O; Avenet P
    J Pharmacol Exp Ther; 2012 Mar; 340(3):706-15. PubMed ID: 22171093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Allen MH; Feifel D; Lesem MD; Zimbroff DL; Ross R; Munzar P; Spyker DA; Cassella JV
    J Clin Psychiatry; 2011 Oct; 72(10):1313-21. PubMed ID: 21294997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxycodone for neuropathic pain and fibromyalgia in adults.
    Gaskell H; Moore RA; Derry S; Stannard C
    Cochrane Database Syst Rev; 2014 Jun; (6):CD010692. PubMed ID: 24956205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.
    San L; Estrada G; Oudovenko N; Vieta E
    BMC Psychiatry; 2017 Apr; 17(1):126. PubMed ID: 28376877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acupuncture for neuropathic pain in adults.
    Ju ZY; Wang K; Cui HS; Yao Y; Liu SM; Zhou J; Chen TY; Xia J
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD012057. PubMed ID: 29197180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder.
    Citrome L
    Int J Clin Pract; 2011 Mar; 65(3):330-40. PubMed ID: 21199198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial.
    Weinstein SM; Abernethy AP; Spruill SE; Pike IM; True Kelly A; Jett LG
    J Pain Symptom Manage; 2012 Apr; 43(4):679-93. PubMed ID: 21983265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a novel chemokine receptor 2 (CCR2)-antagonist in painful diabetic polyneuropathy.
    Kalliomäki J; Jonzon B; Huizar K; O'Malley M; Andersson A; Simpson DM
    Scand J Pain; 2013 Apr; 4(2):77-83. PubMed ID: 29913894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
    Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
    Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Dose Loxapine: Neuromotor Side Effects and Tolerability in Autism Spectrum Disorders.
    Hellings JA; Jadhav M; Jain S; Jadhav S; Genovese A
    J Child Adolesc Psychopharmacol; 2015 Oct; 25(8):618-24. PubMed ID: 26485086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
    Citrome L
    Int J Clin Pract; 2012 Mar; 66(3):318-25. PubMed ID: 22226343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a T-type calcium channel blocker in patients with neuropathic pain: A proof-of-concept, randomized, double-blind and controlled trial.
    Kerckhove N; Pereira B; Soriot-Thomas S; Alchaar H; Deleens R; Hieng VS; Serra E; Lanteri-Minet M; Arcagni P; Picard P; Lefebvre-Kuntz D; Maindet C; Mick G; Balp L; Lucas C; Creach C; Letellier M; Martinez V; Navez M; Delbrouck D; Kuhn E; Piquet E; Bozzolo E; Brosse C; Lietar B; Marcaillou F; Hamdani A; Leroux-Bromberg N; Perier Y; Vergne-Salle P; Gov C; Delage N; Gillet D; Romettino S; Richard D; Mallet C; Bernard L; Lambert C; Dubray C; Duale C; Eschalier A
    Eur J Pain; 2018 Aug; 22(7):1321-1330. PubMed ID: 29577519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens.
    Spyker DA; Riesenberg RA; Cassella JV
    J Clin Pharmacol; 2015 Sep; 55(9):985-94. PubMed ID: 25808074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.
    Kopecky EA; Vaughn B; Lagasse S; O'Connor M
    Drugs Aging; 2017 Aug; 34(8):603-613. PubMed ID: 28600725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.